Toth Financial Advisory Corp Raises Stock Holdings in Abbott Laboratories $ABT

Key Points

• Toth Financial Advisory Corp increased its holdings in Abbott Laboratories by 2.4% in Q2, owning a total of 108,213 shares valued at $14.7 million.
• Several analysts have recently adjusted their price targets for Abbott Laboratories, with an average target set at $145.22 and the stock rated as a "Moderate Buy".
• Abbott Laboratories declared a quarterly dividend of $0.59 per share, which will be paid on November 17th, representing an annualized yield of 1.7%.

Toth Financial Advisory Corp lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 2.4% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 108,213 shares of the healthcare product maker's stock after buying an additional 2,507 shares during the period. Abbott Laboratories makes up 1.7% of Toth Financial Advisory Corp's holdings, making the stock its 13th largest position. Toth Financial Advisory Corp's holdings in Abbott Laboratories were worth $14,718,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC boosted its position in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock valued at $5,850,000 after buying an additional 4,755 shares during the last quarter. Bank Pictet & Cie Europe AG raised its position in Abbott Laboratories by 1.9% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker's stock worth $17,274,000 after acquiring an additional 2,774 shares during the period. Woodline Partners LP bought a new stake in Abbott Laboratories during the 4th quarter valued at about $5,997,000. Fourth Dimension Wealth LLC acquired a new position in shares of Abbott Laboratories in the 4th quarter valued at $43,000. Finally, GTS Securities LLC lifted its position in Abbott Laboratories by 164.2% in the fourth quarter. GTS Securities LLC now owns 11,776 shares of the healthcare product maker's stock valued at $1,332,000 after buying an additional 7,318 shares during the last quarter. Institutional investors own 75.18% of the company's stock.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares in the company, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Trading Up 1.2%

NYSE:ABT traded up $1.65 during trading hours on Friday, reaching $136.22. 11,531,874 shares of the company were exchanged, compared to its average volume of 5,199,671. The stock has a 50 day simple moving average of $130.47 and a 200 day simple moving average of $131.12. The firm has a market cap of $237.09 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 2.58 and a beta of 0.69. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm had revenue of $11.14 billion for the quarter, compared to the consensus estimate of $11.01 billion. During the same period last year, the firm posted $1.14 EPS. Abbott Laboratories's quarterly revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be paid a $0.59 dividend. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is 29.57%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. William Blair raised Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Raymond James Financial dropped their target price on Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a report on Friday, July 18th. Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Royal Bank Of Canada upped their price target on Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Finally, BTIG Research decreased their price target on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $145.22.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.